Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
157.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.20 (0.128%)
Market Cap: £895.35m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Q3 Trading Update

28 Oct 2021 07:00

RNS Number : 4938Q
Elementis PLC
28 October 2021
 

Elementis plc

Q3 Trading Update

Financial recovery continues

Outlook unchanged, in line with expectations

Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, today issues a trading update for the three months ended 30 September 2021.

Third quarter business performance

 

The Group has delivered a strong third quarter performance as trading continues to improve with revenue up 16% on an underlying basis, driven by higher volumes and pricing actions. While there are material global supply chain challenges, such as raw material availability, logistical bottlenecks and rising inflation, we are successfully managing these impacts via supply resiliency, self-help actions and the implementation of price increases. As a result, our 2021 outlook is unchanged.

 

· Coatings continued to perform well with strong revenue growth versus the prior year period, as robust industrial coatings activity more than offset a moderation in European decorative demand. Despite cost inflation headwinds, the combination of pricing actions and continued growth will keep the business on track for improved operating margins versus the prior year.

 

· Personal Care performance improved on the prior year period as demand continued to show signs of recovery from COVID-19 lows, particularly in cosmetics, as social and travel restrictions began to ease, albeit still at levels below 2019. As expected, the new AP Actives plant in India started up in Q3 and a 12 month ramp up is now in progress.

 

· Talc revenue rose modestly on the prior year period as semi-conductor related supply challenges significantly reduced global automotive production. Pricing actions and cost savings, in response to increased logistics and energy costs, are expected to support a sequentially improved second half performance.

· Chromium performance improved on the prior year, as demand strengthened in areas such as aerospace and refractory. Global industry utilisation levels continued to improve and, if sustained, should result in improved pricing in 2022.

 

We have continued to successfully deliver against our Innovation, Growth and Efficiency strategy. In 2021 we expect to launch over 20 new products, win more than $35m of new business, and deliver $10m of in year cost savings.

Outlook

 

The full year outlook remains unchanged; the Group expects to deliver an improved financial performance and a reduction in leverage, in line with expectations.

 

The second half of the year is expected to follow a normal level of seasonality, with continued demand recovery and self-help actions mitigating the impact of near-term margin headwinds from accelerating cost inflation and supply chain constraints.

 

Commenting on the performance, CEO, Paul Waterman said,

"We have delivered a strong third quarter performance, have good trading momentum and are taking proactive steps to mitigate both rising inflation and global supply chain challenges. The delivery of our strategy, alongside a continued post COVID-19 demand recovery, is expected to drive a material, multi-year performance improvement, underpin the delivery of our medium-term Group financial objectives and generate significant shareholder value."

 

Enquiries

Elementis plc

James Curran, Investor Relations Tel: 020 7067 2994

 

Tulchan

Martin Robinson Tel: 020 7353 4200

Olivia Peters

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUBRBRAKURUAA
Date   Source Headline
31st Oct 20237:00 amRNSThird Quarter Trading Update
2nd Oct 20239:34 amRNSTotal Voting Rights
20th Sep 202312:09 pmRNSResponse to open letter from Franklin Templeton
12th Sep 20233:13 pmRNSDirector Declaration
8th Sep 20239:30 amRNSHolding(s) in Company
1st Sep 20239:49 amRNSBlock listing Interim Review
1st Sep 20239:42 amRNSTotal Voting Rights
1st Aug 20239:44 amRNSTotal Voting Rights
27th Jul 20232:16 pmRNSHolding(s) in Company
27th Jul 20237:00 amRNSHalf-year Report
20th Jul 202312:58 pmRNSHolding(s) in Company
3rd Jul 202310:21 amRNSTotal Voting Rights
29th Jun 20234:29 pmRNSDirector/PDMR Shareholding
23rd Jun 20239:32 amRNSDirector/PDMR Shareholding
30th May 20238:06 amRNSDirector Declaration
2nd May 20239:37 amRNSTotal Voting Rights
26th Apr 20232:12 pmRNSResult of AGM
26th Apr 20237:00 amRNSAGM Trading Statement
17th Apr 202310:15 amRNSDirector/PDMR Shareholding
17th Apr 202310:10 amRNSDirector/PDMR Shareholding
13th Apr 20234:24 pmRNSDirector/PDMR Shareholding
3rd Apr 202311:28 amRNSDirector Declaration
3rd Apr 20239:34 amRNSTotal Voting Rights
24th Mar 20239:27 amRNSDirector/PDMR Shareholding
22nd Mar 20234:02 pmRNSAnnual Financial Report & Notice of AGM
17th Mar 20232:58 pmRNSAdditional Listing
14th Mar 20237:30 amRNSDirector Declaration
9th Mar 20232:50 pmRNSDirector/PDMR Shareholding
9th Mar 20232:47 pmRNSDirector/PDMR Shareholding
7th Mar 20237:00 amRNSPreliminary results year ended 31 December 2022
1st Mar 20239:53 amRNSBlock listing Interim Review
1st Mar 20239:39 amRNSTotal Voting Rights
31st Jan 20233:04 pmRNSSale of Chromium business
19th Jan 20237:00 amRNSTrading Update
3rd Jan 20239:47 amRNSTotal Voting Rights
8th Dec 20222:10 pmRNSDirector/PDMR Shareholding
30th Nov 20227:00 amRNSSale of Chromium business
23rd Nov 20223:54 pmRNSHolding(s) in Company
16th Nov 20221:43 pmRNSHolding(s) in Company
10th Nov 20229:40 amRNSHolding(s) in Company
10th Nov 20227:00 amRNSDirectorate Change
1st Nov 20229:48 amRNSTotal Voting Rights
31st Oct 20223:23 pmRNSHolding(s) in Company
26th Oct 20227:00 amRNSQ3 Trading Update
18th Oct 20223:13 pmRNSHolding(s) in Company
3rd Oct 20229:39 amRNSTotal Voting Rights
29th Sep 202212:45 pmRNSDirector/PDMR Shareholding
29th Sep 202210:12 amRNSDirector/PDMR Shareholding
22nd Sep 202211:17 amRNSDirector/PDMR Shareholding
21st Sep 20224:58 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.